755 related articles for article (PubMed ID: 30203184)
1. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
2. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
3. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
4. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
7. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
8. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
9. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
[TBL] [Abstract][Full Text] [Related]
10. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA damage in SCLC.
Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
[TBL] [Abstract][Full Text] [Related]
13. Personalized Therapy of Small Cell Lung Cancer.
Schneider BJ; Kalemkerian GP
Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
15. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer].
Huang B; Duan Y
Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):239-244. PubMed ID: 31014443
[TBL] [Abstract][Full Text] [Related]
17. [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer].
Zhang SY; Wang Y
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):98-103. PubMed ID: 33472320
[TBL] [Abstract][Full Text] [Related]
18. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Meder L; Schuldt P; Thelen M; Schmitt A; Dietlein F; Klein S; Borchmann S; Wennhold K; Vlasic I; Oberbeck S; Riedel R; Florin A; Golfmann K; Schlößer HA; Odenthal M; Buettner R; Wolf J; Hallek M; Herling M; von Bergwelt-Baildon M; Reinhardt HC; Ullrich RT
Cancer Res; 2018 Aug; 78(15):4270-4281. PubMed ID: 29776963
[TBL] [Abstract][Full Text] [Related]
19. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]